EUVIMEDEUVIMED entdecken
Open Access

De novo design of drug-binding proteins with predictable binding energy and specificity

Lei Lu iD, Xuxu Gou iD, Sophia K Tan iD, Samuel I Mann iD, Hyunjun Yang iD, Xiaofang Zhong, Dimitrios Gazgalis iD, Jesús Valdiviezo iD, Hyunil Jo iD, Yibing Wu, Morgan E Diolaiti iD, Alan Ashworth iD und 2 weitere

Science · 05.04.2024 · 384 (6691) · 106-112

DOI: 10.1126/science.adl5364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 05.04.2024. Verfasst von Lei Lu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry & Cardiovascular Research Institute, University of California, San Francisco, CA 94158, USA. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Proteins, Protein Engineering, Pharmacophore. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The de novo design of small molecule–binding proteins has seen exciting recent progress; however, high-affinity binding and tunable specificity typically require laborious screening and optimization after computational design. We developed a computational procedure to design a protein that recognizes a common pharmacophore in a series of poly(ADP-ribose) polymerase–1 inhibitors. One of three designed proteins bound different inhibitors with affinities ranging from

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsProteinsProtein EngineeringPharmacophoreHumansBinding SitesLigandsMolecular Dynamics SimulationProtein Binding

Substanzen

LigandsPoly(ADP-ribose) Polymerase InhibitorsProteins

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry & Cardiovascular Research Institute, University of California, San Francisco, CA 94158, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA.
  • Department of Chemistry, University of California, Riverside, CA 92521, USA.
  • Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA.

ORCID-Profile: Lei Lu, Xuxu Gou, Sophia K Tan, Samuel I Mann, Hyunjun Yang, Dimitrios Gazgalis, Jesús Valdiviezo, Hyunil Jo, Morgan E Diolaiti, Alan Ashworth, Nicholas F Polizzi, William F DeGrado

Förderung

  • NIA NIH HHS
  • NIGMS NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Lu, L., Gou, X., Tan, S. K., Mann, S. I., Yang, H., Zhong, X., Gazgalis, D., Valdiviezo, J., Jo, H., Wu, Y., Diolaiti, M. E., Ashworth, A., Polizzi, N. F., & DeGrado, W. F. (2024). De novo design of drug-binding proteins with predictable binding energy and specificity. Science, 384(6691), 106-112. https://doi.org/10.1126/science.adl5364

Vancouver

Lu L, Gou X, Tan SK, Mann SI, Yang H, Zhong X, et al. De novo design of drug-binding proteins with predictable binding energy and specificity. Science. 2024;384(6691):106-112. doi:10.1126/science.adl5364

BibTeX
@article{Lu2024,
  author = {Lu, Lei and Gou, Xuxu and Tan, Sophia K and Mann, Samuel I and Yang, Hyunjun and Zhong, Xiaofang and Gazgalis, Dimitrios and Valdiviezo, Jesús and Jo, Hyunil and Wu, Yibing and Diolaiti, Morgan E and Ashworth, Alan and Polizzi, Nicholas F and DeGrado, William F},
  title = {De novo design of drug-binding proteins with predictable binding energy and specificity},
  journal = {Science},
  year = {2024},
  volume = {384},
  number = {6691},
  pages = {106--112},
  doi = {10.1126/science.adl5364}
}
Kostenlos starten →